SMT201300072B - Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide - Google Patents

Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide

Info

Publication number
SMT201300072B
SMT201300072B SM201300072T SM201300072T SMT201300072B SM T201300072 B SMT201300072 B SM T201300072B SM 201300072 T SM201300072 T SM 201300072T SM 201300072 T SM201300072 T SM 201300072T SM T201300072 B SMT201300072 B SM T201300072B
Authority
SM
San Marino
Prior art keywords
dimethylmorfolin
carbossammide
bifenyl
fluoromethoxy
pyridin
Prior art date
Application number
SM201300072T
Other languages
English (en)
Italian (it)
Inventor
Raeann Wu
Joginder Singh Bajwa
Stephanie Kay Dodd
Liladhar Mulidhar Waykole
La Cruz Marilyn De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201300072(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201300072B publication Critical patent/SMT201300072B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201300072T 2008-09-17 2013-06-26 Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide SMT201300072B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17
PCT/US2009/056918 WO2010033481A1 (en) 2008-09-17 2009-09-15 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide

Publications (1)

Publication Number Publication Date
SMT201300072B true SMT201300072B (it) 2013-09-06

Family

ID=41228716

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201300072T SMT201300072B (it) 2008-09-17 2013-06-26 Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide

Country Status (39)

Country Link
US (3) US8063043B2 (uk)
EP (1) EP2342198B1 (uk)
JP (2) JP4897938B2 (uk)
KR (2) KR101129088B1 (uk)
CN (1) CN102159570B (uk)
AR (2) AR073591A1 (uk)
AU (1) AU2009293444B2 (uk)
BR (2) BR122020009045B1 (uk)
CA (1) CA2736751C (uk)
CL (1) CL2011000551A1 (uk)
CO (1) CO6351744A2 (uk)
CR (1) CR20110126A (uk)
CU (1) CU23860B1 (uk)
DK (1) DK2342198T3 (uk)
DO (1) DOP2011000082A (uk)
EA (1) EA020048B1 (uk)
EC (1) ECSP11010985A (uk)
ES (1) ES2418485T3 (uk)
GE (1) GEP20125592B (uk)
HK (1) HK1156628A1 (uk)
HN (1) HN2011000745A (uk)
HR (1) HRP20130597T1 (uk)
IL (1) IL211412A (uk)
JO (1) JO2889B1 (uk)
MA (1) MA32717B1 (uk)
MX (1) MX2011002805A (uk)
MY (1) MY151100A (uk)
NI (1) NI201100051A (uk)
NZ (1) NZ591420A (uk)
PE (1) PE20110292A1 (uk)
PL (1) PL2342198T3 (uk)
PT (1) PT2342198E (uk)
SI (1) SI2342198T1 (uk)
SM (1) SMT201300072B (uk)
SV (1) SV2011003857A (uk)
TW (1) TWI367883B (uk)
UA (1) UA103049C2 (uk)
WO (1) WO2010033481A1 (uk)
ZA (1) ZA201101579B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
WO2014128661A1 (en) 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
WO2016155630A1 (zh) * 2015-03-30 2016-10-06 苏州晶云药物科技有限公司 N-[6-(顺式-2,6-二甲基吗啉-4-基)吡啶-3-基]-2-甲基-4'-(三氟甲氧基)[1,1'-联苯]-3-甲酰胺单磷酸盐的晶型及其制备方法
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1670785T1 (sl) * 2003-10-02 2010-10-29 Pharmacia & Upjohn Co Llc Soli in polimorfi spojine indolinona, substituirani s pirolom
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
MX2011002805A (es) 2011-04-11
CA2736751A1 (en) 2010-03-25
WO2010033481A1 (en) 2010-03-25
AU2009293444B2 (en) 2012-03-15
EP2342198A1 (en) 2011-07-13
HK1156628A1 (uk) 2012-06-15
PT2342198E (pt) 2013-07-10
NI201100051A (es) 2011-09-08
KR20110056325A (ko) 2011-05-26
CR20110126A (es) 2011-04-27
AR113778A2 (es) 2020-06-10
DK2342198T3 (da) 2013-07-01
CU20110055A7 (es) 2011-12-28
AR073591A1 (es) 2010-11-17
US20120214810A1 (en) 2012-08-23
EA020048B1 (ru) 2014-08-29
DOP2011000082A (es) 2011-04-15
SV2011003857A (es) 2011-05-16
MA32717B1 (fr) 2011-10-02
AU2009293444A1 (en) 2010-03-25
PL2342198T3 (pl) 2013-08-30
US20120035174A1 (en) 2012-02-09
TW201016686A (en) 2010-05-01
MY151100A (en) 2014-04-15
CN102159570B (zh) 2014-01-15
JP2012097104A (ja) 2012-05-24
EA201100501A1 (ru) 2011-10-31
IL211412A (en) 2014-07-31
CA2736751C (en) 2012-10-23
ECSP11010985A (es) 2011-05-31
CU23860B1 (es) 2013-02-26
JP2012502912A (ja) 2012-02-02
KR101129088B1 (ko) 2012-03-23
HN2011000745A (es) 2014-01-06
CN102159570A (zh) 2011-08-17
BR122020009045A2 (pt) 2020-11-10
ES2418485T3 (es) 2013-08-14
EP2342198B1 (en) 2013-04-03
UA103049C2 (uk) 2013-09-10
BRPI0918629B1 (pt) 2021-04-13
US20110178085A1 (en) 2011-07-21
SI2342198T1 (sl) 2013-07-31
HRP20130597T1 (en) 2013-07-31
TWI367883B (en) 2012-07-11
GEP20125592B (en) 2012-07-25
US8063043B2 (en) 2011-11-22
BR122020009045B1 (pt) 2022-08-02
JO2889B1 (en) 2015-03-15
CL2011000551A1 (es) 2011-07-15
BRPI0918629B8 (pt) 2021-05-25
PE20110292A1 (es) 2011-05-17
JP4897938B2 (ja) 2012-03-14
NZ591420A (en) 2012-07-27
BRPI0918629A2 (pt) 2020-10-27
KR20120015363A (ko) 2012-02-21
CO6351744A2 (es) 2011-12-20
ZA201101579B (en) 2011-11-30
IL211412A0 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
SMT201300072B (it) Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
ATE541850T1 (de) Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0810349A2 (pt) "artigo"
BRPI0817169A2 (pt) "artigos"
PT2044036E (pt) Derivados de [4,5′]bipirimidinil-6,4′-diamina como inibidores de proteína quinase
DK2238213T3 (da) Trans-chlor-3,3,3-trifluorpropen til anvendelse i køleindretninger
EP1845086A4 (en) N-SUBSTITUTED N-METHOXYCARBAMATES BY 2-SUBSTITUTED PHENYL GROUPS, THEIR SYNTHESIS AND THEIR APPLICATIONS
HK1149268A1 (en) Pyrazine derivatives and their use as protein kinase inhbitors
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0908050A2 (pt) Furo-e tieno[3,2-c]piridinas
DE602006014832D1 (de) Rauchartikel
ATE449080T1 (de) 4-phenyl-6-substituierte pyrimidin-2- carbonitrilderivate
IL212070A (en) Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
BRPI0914354A2 (pt) "métodos e artigos"
EP2184277A4 (en) ARYLPYRIMIDINE DERIVATIVES, METHODS OF PREPARATION AND PHARMACEUTICAL USES OF THE DERIVATIVES
BRPI0907217A2 (pt) Modelo de cabeça em o.
HK1159018A1 (en) Evaluating heparin preparations for pharmaceutical use
EP2348019A4 (en) 1,2-DIAZETTIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME
BRPI0907749A2 (pt) Derivados de 3,8-diaminotetrahidroquinolina
DE602007005878D1 (de) Verwendung von 1,2-Dihydroperillaldehyd in Geschmacksanwendungen
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents